Results 11 to 20 of about 839,337 (241)

Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases [PDF]

Nature Communications
Primary vaccination with mRNA-1273 (100-µg) was safe and efficacious at preventing coronavirus disease 2019 (COVID-19) in the previously reported, blinded Part A of the phase 3 Coronavirus Efficacy (COVE; NCT04470427) trial in adults (≥18 years) across ...
Lindsey R. Baden, Hana M. El Sahly, Brandon Essink, Dean Follmann, Gregory Hachigian, Cynthia Strout, J. Scott Overcash, Susanne Doblecki-Lewis, Jennifer A. Whitaker, Evan J. Anderson, Kathleen Neuzil, Lawrence Corey, Frances Priddy, Joanne E. Tomassini, Mollie Brown, Bethany Girard, Dina Stolman, Veronica Urdaneta, Xiaowei Wang, Weiping Deng, Honghong Zhou, Avika Dixit, Rituparna Das, Jacqueline M. Miller, the COVE Trial Consortium   +24 more
doaj   +3 more sources

Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase [PDF]

New England Journal of Medicine, 2021
BACKGROUND At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease 2019 (Covid-19).
Anderson, EJ, August, A, Babiker, A, Baden, LR, Bruno, R, Campbell, TB, Clark, J, Clouting, H, Cooper, LA, Corey, L, Deng, W, Doblecki-Lewis, S, Eder, F, El Sahly, HM, Ellenberg, SS, Essink, B, Faugno, A, Feldman, G, Fichtenbaum, CJ, Fix, A, Follmann, D, Gilbert, P, Gorman, R, Graham, BS, Griffin, M, Hamill, RJ, Hamilton, H, Han, S, Han-Conrad, L, Horwith, G, Huynh, C, Jackson, LA, Janes, H, Joffe, S, Kalil, J, Kennelly, C, Leav, B, Ledgerwood, JE, Levin, M, Levine, MM, Lipsitz, L, Makgoba, MW, Manzo, D, Marovich, M, Martin, JM, Mascola, JR, Miller, J, Moore, RH, Mytle, N, Neuzil, KM, Pajon, R, Pavetto, C, Polakowski, L, Rankin, B, Rosenberg, ES, Schödel, F, Tomassini, JE, Tong, X, Treanor, J, Tsiatis, AA, Whitley, RJ, Zervos, M, Zhou, H   +62 more
core   +2 more sources

Comparative effectiveness of BNT162b2 versus mRNA-1273 covid-19 vaccine boosting in England: matched cohort study in OpenSAFELY-TPP [PDF]

British medical journal, 2023
Objective To compare the effectiveness of the BNT162b2 mRNA (Pfizer-BioNTech) and mRNA-1273 (Moderna) covid-19 vaccines during the booster programme in England. Design Matched cohort study, emulating a comparative effectiveness trial.
Andrews, Colm D, Bacon, Sebastian CJ, Curtis, Helen J, Goldacre, Ben, Hernán, Miguel A, Horne, Elsie MF, Hulme, William J, Keogh, Ruth H, MacKenna, Brian, Mehrkar-Asl, Amir, Morley, Jessica, Palmer, Tom M, Parker, Edward PK, Sterne, Jonathan AC, Walker, Alex J, Walker, Venexia, Williamson, Elizabeth J   +16 more
core   +6 more sources

Safety and durability of mRNA-1273–induced SARS-CoV-2 immune responses in adolescents: results from the phase 2/3 TeenCOVE trialResearch in context [PDF]

EClinicalMedicine
Summary: Background: Longitudinal changes in vaccination-induced immune response remain inadequately characterized in adolescents. We present long-term safety, immunogenicity, and COVID-19 incidence following a 2-dose mRNA-1273 100-μg primary series ...
Amparo L. Figueroa, Kashif Ali, Gary Berman, Honghong Zhou, Weiping Deng, Wenqin Xu, Stephanie Lussier, Bethany Girard, Frank J. Dutko, Karen Slobod, Anne Yeakey, Frances Priddy, Jacqueline M. Miller, Rituparna Das   +13 more
doaj   +2 more sources

Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age [PDF]

Vaccines
Background/Objectives: Streptococcus pneumoniae with, or following, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been associated with increased mortality, particularly in older adults.
Tosin Omole, Enrique Pelayo, Aaron S. Weinberg, Spyros Chalkias, Zelalem Endale, Gretchen Tamms, Tina M. Sterling, Lori Good, Tulin Shekar, Morgan Johnson, Natalie Banniettis, Ulrike K. Buchwald, Alejandra Esteves-Jaramillo   +12 more
doaj   +2 more sources

Immunogenicity of mRNA-1273 and BNT162b2 in Immunocompromised Patients: Systematic Review and Meta-analysis Using GRADE [PDF]

Infectious Diseases and Therapy
Introduction Immunocompromised (IC) patients mount poor immune responses to vaccination. Higher-dose coronavirus disease 2019 (COVID-19) vaccines may offer increased immunogenicity.
Sushma Kavikondala, Katrin Haeussler, Xuan Wang, Anne Spellman, Mary T. Bausch-Jurken, Pawana Sharma, Mohammadreza Amiri, Anna Krivelyova, Sonam Vats, Maria Nassim, Nitendra Kumar, Nicolas Van de Velde   +11 more
doaj   +2 more sources

Clinical Course, Outcomes, and Risk Factors of Myocarditis and Pericarditis Following Administration of mRNA-1273 Vaccination: A Protocol for a Federated Real-World Evidence Vaccine Safety Study Using Data from Five European Data Sources [PDF]

Vaccines
Background: Myocarditis and pericarditis are recognised risks following COVID-19 vaccination, including the mRNA-1273 vaccine. Most cases occur shortly following the second dose of this vaccine, and incidence is highest among young males. However, little
Laura C. Zwiers, Diederick E. Grobbee, Rob Schneijdenberg, Corine Baljé, Samantha St. Laurent, Daina B. Esposito, Lei Zhu, Veronica V. Urdaneta, Magalie Emilebacker, Daniel Weibel, Felipe Villalobos, Carlo Alberto Bissacco, Arantxa Urchueguía Fornes, Juan José Carreras-Martínez, Anteneh A. Desalegn, Angela Lupattelli, Lei Wang, Jannik Wheler, Vera Ehrenstein, Denise Morris, Catherine Fry, Marjolein Jansen, Brianna M. Goodale, David S. Y. Ong   +23 more
doaj   +2 more sources

mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions

Science Translational Medicine, 2022
The successful development of several coronavirus disease 2019 (COVID-19) vaccines has substantially reduced morbidity and mortality in regions of the world where the vaccines have been deployed.
Paulina Kapłonek, Deniz Cizmeci, Stephanie Fischinger, Ai‐ris Y. Collier, Todd J. Suscovich, Caitlyn Linde, Thomas Broge, Colin Mann, Fatima Amanat, Diana Dayal, Justin Rhee, Michael de St. Aubin, Eric J. Nilles, Elon R. Musk, Anil Menon, Erica Ollmann Saphire, Florian Krammer, Douglas A. Lauffenburger, Dan H. Barouch, Galit Alter   +19 more
openalex   +3 more sources

Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients [PDF]

Clinical Infectious Diseases, 2021
SARS-CoV-2 proteins were measured in longitudinal plasma samples collected from 13 participants who received two doses of mRNA-1273 vaccine. 11 of 13 participants showed detectable levels of SARS-CoV-2 protein as early as day one after first vaccine ...
Alana F. Ogata, Chi‐An Cheng, Michaël Desjardins, Yasmeen Senussi, Amy C Sherman, Megan Powell, Lewis A. Novack, Salena S Von, Xiaofang Li, Lindsey R. Baden, David R. Walt   +10 more
openalex   +2 more sources

Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273 [PDF]

Journal of the American Medical Association (JAMA), 2021
Methods | Healthcareworkersatatertiarycarecenter(Ziekenhuis Oost-Limburg, Belgium) who were scheduled for vaccination with 2 doses of either mRNA-1273 or BNT162b2 were invited to participate in this prospective cohort.
Deborah Steensels, Noëlla Pierlet, Joris Penders, Dieter Mesotten, Line Heylen   +4 more
openalex   +2 more sources